EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Safety gaps in pediatric liquid antihypertensive compounding: a scoping review and regulatory-based safety assessment

Fabrício Costa Fanhani, Laiene Antunes Alves, Marcel Henrique Marcondes Sari, Antônio Eduardo Matoso Mendes, Roberto Pontarolo, Luana Mota Ferreira

European Journal of Pharmaceutics and Biopharmaceutics · 2026

DOI: 10.1016/j.ejpb.2026.115153 ↗

Kurz gefasst

Scoping Review in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Fabrício Costa Fanhani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal do Paraná, Curitiba, Brazil. Hauptthemen laut MEDLINE: Excipients, Antihypertensive Agents, Drug Compounding. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Universidade Federal do Paraná, Osteo Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Extemporaneous liquid antihypertensive formulations are widely used in pediatrics but frequently lack detailed reporting of excipient safety data, particularly regarding age-specific physiological vulnerability and cumulative exposure. METHODS: A scoping review was conducted in accordance with PRISMA-ScR guidelines to map excipients used in pediatric extemporaneous antihypertensive liquid formulations. A regulatory-oriented assessment was applied, emphasizing age-appropriate safety considerations and exposure-based risk principles, including theoretical daily intake expressed as mg/kg/day. RESULTS: Forty-two studies were included. Reporting of excipient concentrations, age targets, and safety justifications was heterogeneous and often incomplete. Vehicles, co-solvents, preservatives, buffers, antioxidants, surfactants, and flavoring agents were identified, with selection typically driven by a focus on physicochemical stability rather than patient-centered criteria, such as age-appropriate excipient safety, dose flexibility, and acceptable volumes. Exposure-based considerations were addressed by a limited number of studies (n = 5). Exposure calculations based on typical pediatric dosing showed that concentrations considered acceptable in adult formulations may translate into clinically relevant toxicity risks in neonates and infants. Based on observed patterns, a conceptual risk stratification framework was developed to categorize excipients according to age-dependent toxicity, cumulative dose burden, and functional tolerability. CONCLUSIONS: The available literature on compounding antihypertensive formulations mainly emphasizes physicochemical performance, with less attention given to exposure-related safety parameters in pediatric patients. Integrating total daily excipient exposure metrics and structured justification for excipient selection may improve alignment with regulatory expectations and support safer, patient-centered compounding practices in pediatric clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExcipientsAntihypertensive AgentsDrug CompoundingHumansChildPediatricsChemistry, Pharmaceutical

Stichwörter der Autor:innen

Antihypertensive agentsDrug compoundingExcipientsInfantOff-label usePatient safetyPediatrics

Substanzen

ExcipientsAntihypertensive Agents

Autor:innen und Institutionen

  • Programa de Pós-graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal do Paraná, Curitiba, Brazil.
  • Departamento de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Paraná, Brazil.
  • Programa de Pós-graduação em Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal do Paraná, Curitiba, Brazil; Departamento de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Paraná,…

Förderung

  • National Council for Scientific and Technological Development
  • Universidade Federal do Paraná
  • Osteo Science Foundation

Zitieren

APA

Fanhani, F. C., Alves, L. A., Sari, M. H. M., Mendes, A. E. M., Pontarolo, R., & Ferreira, L. M. (2026). Safety gaps in pediatric liquid antihypertensive compounding: a scoping review and regulatory-based safety assessment. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115153

Vancouver

Fanhani FC, Alves LA, Sari MHM, Mendes AEM, Pontarolo R, Ferreira LM. Safety gaps in pediatric liquid antihypertensive compounding: a scoping review and regulatory-based safety assessment. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115153

BibTeX
@article{Fanhani2026,
  author = {Fanhani, Fabrício Costa and Alves, Laiene Antunes and Sari, Marcel Henrique Marcondes and Mendes, Antônio Eduardo Matoso and Pontarolo, Roberto and Ferreira, Luana Mota},
  title = {Safety gaps in pediatric liquid antihypertensive compounding: a scoping review and regulatory-based safety assessment},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  doi = {10.1016/j.ejpb.2026.115153}
}
Kostenlos starten →